ArticleObesity surgery2026
Five-Year Outcomes of Sleeve Gastrectomy with Transit Bipartition in Women with Severe Obesity and Insulin-Treated Type 2 Diabetes: A Prospective Single-Center Cohort Study of 35 Women.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFive-year data on metabolic durability, nutritional outcomes, and late morbidity after sleeve gastrectomy with transit bipartition (SG + TB) remain limited. We evaluated glycemic, weight, nutritional, and safety outcomes in women with severe obesity and insulin-treated type 2 diabetes mellitus (T2DM).
methodsThis prospective single-center follow-up included 35 women who underwent laparoscopic SG + TB in 2016-2017. At 5 years, 30/35 (85.7%) retained SG + TB anatomy and had complete efficacy data; weight and HbA1c were available in one additional revised patient (31/35, 88.6%). T2DM remission was defined as HbA1c < 6.5% at least 3 months after stopping glucose-lowering pharmacotherapy. Nutritional assessment used a prespecified limited biochemical panel.
resultsIn the 30-patient anatomy-retained complete-case cohort, mean HbA1c decreased from 9.2 ± 1.0% to 5.5 ± 0.7%, body weight from 118.0 ± 10.6 to 75.6 ± 6.8 kg, and mean total weight loss was 35.7 ± 5.1%. Medication-free T2DM remission was 23/30 (76.7%; 95% CI, 59.1-88.2%); the conservative all-enrolled estimate was 23/35 (65.7%; 95% CI, 49.2-79.2%). At year 5, hypoalbuminemia was 20.0%, low serum iron 30.0%, vitamin B12 deficiency 13.3%, and vitamin D deficiency 73.3%; 27/30 (90.0%) had at least one predefined biochemical abnormality. Two patients required an SG + TB-related invasive intervention, including one revision; two additional patients underwent laparoscopic cholecystectomy.
conclusionSG + TB was associated with substantial 5-year weight loss and glycemic improvement, but the lower all-enrolled remission estimate highlights attrition and revision-related exclusion. Biochemical abnormalities and clinically important gastrointestinal morbidity show that preserved duodenal continuity does not eliminate potential hypoabsorptive consequences. Lifelong metabolic and nutritional surveillance is warranted.
Identifiers
42862453What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.